Direct-to-consumer (DTC) genetic testing for disease susceptibility is largely dominated by 2 extremes—narrow tests that only screen for a few variants and broad tests that include dozens of genes. These tests may lack clinical utility for consumers wanting to understand their disease risks. In the context of genetic testing, clinical utility refers to the ability of a test to generate results that can be used to reduce morbidity and mortality through the adoption of medical management strategies, including screening and surgery. Narrow and broad tests, however, lack clinical utility for different reasons. Narrow tests are often incomplete, and only include a limited number of relevant variants.1 Broad tests, by contrast, are concerning because they often include genes for which well-established risk estimates, medical management guidelines, or both may be absent.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kilbride MK, Bradbury AR. The Need to Improve the Clinical Utility of Direct-to-Consumer Genetic Tests: Either Too Narrow or Too Broad. JAMA. 2020;323(15):1443–1444. doi:10.1001/jama.2019.22504
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: